AL050-ABC
Parkinson's Disease, Gaucher Disease, Lewy Body Dementia
PreclinicalActive
Key Facts
Indication
Parkinson's Disease, Gaucher Disease, Lewy Body Dementia
Phase
Preclinical
Status
Active
Company
About Alector
Founded in 2013 and publicly traded on Nasdaq, Alector is on a mission to slow and prevent neurodegenerative diseases by harnessing insights from human genetics, immunology, and neuroscience. The company has built a robust pipeline of potential first- and best-in-class candidates, with its lead program, latozinemab (AL001), in a pivotal Phase 3 trial for frontotemporal dementia and AL101 in Phase 2 for Alzheimer's disease via a major collaboration with GSK. Alector's strategy combines internal R&D with high-value partnerships, supported by a seasoned leadership team with deep expertise in drug discovery and development.
View full company profile